NDAORALTABLET
Approved
Aug 2002
Lifecycle
LOE Approaching
Competitive Pressure
35/100
Clinical Trials
20
Data completeness
6/8 — Strong
LEXAPRO (escitalopram) by AbbVie is escitalopram, the s-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (cns) resulting from its inhibition of cns neuronal reuptake of serotonin (5-ht). Approved for major depressive disorder, generalized anxiety disorder. First approved in 2002.
Drug data last refreshed 23h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXAPRO (escitalopram) is an oral selective serotonin reuptake inhibitor (SSRI) approved by the FDA in August 2002 for the treatment of anxiety disorders. As the active S-enantiomer of citalopram, it works by inhibiting neuronal reuptake of serotonin in the central nervous system, thereby potentiating serotonergic activity. LEXAPRO is a foundational SSRI in the anxiety treatment landscape and has been a market standard for over two decades.
$0.0BPart D
0mo to LOEMechanism of Action
escitalopram, the S-enantiomer of racemic citalopram, is presumed to be linked to potentiation of serotonergic activity in the central nervous system (CNS) resulting from its inhibition of CNS neuronal reuptake of serotonin (5-HT).
Indications (2)
Worked on LEXAPRO at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.